Research Article
Serum Galectin-3 as a Potential Predictive Biomarker Is Associated with Poststroke Cognitive Impairment
Table 1
Baseline data of patients according to cognitive functions.
| | Characteristics | All patients () | Non-PSCI () | PSCI () | |
| | Age, years | | | | 0.468 | | Gender, male, (%) | 248 (59.6) | 96 (58.5) | 153 (60.7) | 0.658 | | Education, years | | | | 0.301 | | BMI, kg/m2 | | | | 0.220 | | Admission NIHSS | 6 (3-8) | 6 (3-7) | 6 (3-8) | 0.712 | | Vascular risk factors,(%) | | HP | 207 (49.8) | 80 (48.8) | 127 (50.4) | 0.747 | | DM | 122 (29.3) | 47 (28.7) | 75 (29.8) | 0.809 | | HLP | 160 (38.5) | 61 (37.2) | 99 (39.3) | 0.668 | | AF | 36 (8.7) | 15 (9.1) | 21 (8.3) | 0.628 | | CHD | 85 (20.4) | 33 (20.1) | 52 (20.6) | 0.849 | | Current smoking | 128 (30.8) | 50 (30.5) | 78 (31.0) | 0.920 | | Current drinking | 149 (35.8) | 59 (36.0) | 90 (35.7) | 0.957 | | TOAST classification,(%) | | Large-artery atherosclerosis | 255 (61.3) | 99 (60.4) | 156 (62.0) | 0.753 | | Small vessel occlusion | 63 (15.1) | 24 (14.6) | 39 (15.5) | 0.815 | | Cardioembolism | 45 (10.8) | 19 (11.6) | 26 (10.3) | 0.684 | | Other cause | 29 (7.0) | 12 (7.3) | 17 (6.7) | 0.823 | | Undetermined | 24 (5.8) | 10 (6.1) | 14 (5.6) | 0.817 | | Clinical laboratory tests | | Leukocyte, 109/L | | | | 0.133 | | Hemoglobin, g/L | | | | 0.120 | | CRP, mg/L | | | | 0.061 | | Galectin-3, ng/mL | | | | <0.001 |
|
|
Abbreviations: PSCI: poststroke cognitive impairment; BMI: body mass index; NHISS: National Institute of Health Stroke Scale; HP: hypertension; DM: diabetes mellitus; HLP: hyperlipidemia; AF: atrial fibrillation; CHD: coronary heart disease; TOAST: Trial of ORG 10172 in Acute Stroke Treatment; CRP: C–reactive protein.
|
